
WEDNESDAY, Nov. 1, 2023 A new gene therapy for sickle cell disease was deemed safe by a U.S. Food and Drug Administration advisory panel on Tuesday, paving the way for full approval by early December. The FDA had already decided that the therapy, known as exa-cel, was effective. Developed by Vertex Pharmaceuticals of Boston and… read on > read on >